SPECIAL NOTICE
A -- LAWRENCE LIVERMORE NATIONAL LABORATORY SEEKS LICENSEES TO COMMERCIALIZE ITS OPTO-ACOUSTIC RECANALIZATION SYSTEM
- Notice Date
- 11/18/2003
- Notice Type
- Special Notice
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue L-795, Livermore, CA, 94550
- ZIP Code
- 94550
- Solicitation Number
- Reference-Number-FBO61-04
- Response Due
- 12/19/2003
- Archive Date
- 12/22/2003
- Point of Contact
- Connie Pitcock, Administration, Phone 925-422-1072, Fax 925-423-8988,
- E-Mail Address
-
pitcock1@llnl.gov
- Description
- LAWRENCE LIVERMORE NATIONAL LABORATORY SEEKS LICENSEES TO COMMERCIALIZE ITS OPTO-ACOUSTIC RECANALIZATION SYSTEM Announcement: Lawrence Livermore National Laboratory (LLNL), operated by the University of California under contract with the U.S. Department of Energy (DOE), seeks licensees to commercialize its opto-acoustic recanalization (OAR) system. LLNL?s OAR System is directed to the removal of blockages in tubular tissues and organs. More specifically, it relates to the removal of intravascular occlusions such as antherosclerotic plaque or thrombus. The OAR technology utilizes an optically activated transducer for generating acoustic vibrations in a biological medium. Energy for operating the transducer is provided optically by laser light. Pulsed laser light is absorbed in the working fluid of the transducer to generate a thermal pressure creating adiabatic expansion of the transducer head such that it does work against the ambient medium. The transducer returns to its original state by a process of thermal cooling. The motion of the transducer within the ambient medium transmits acoustic energy into the medium. By pulsing the laser at a high repetition rate, an ultrasonic radiation field can be established locally in the medium. This method of producing ultrasonic vibrations can be used in vivo for the treatment of stroke-related conditions, particularly for dissolving thrombus. The catheter may also incorporate anti-thrombolytic drug treatments as an adjunct therapy and it may be operated in conjunction with ultrasonic detection equipment for imaging and feedback control. LLNL has a portfolio of patents that cover this technology: U. S. Patent 5,944,687, ?Opto-Acoustic Transducer for Medical Applications?, issued 8/31/99; U. S. Patent 6,022,309, ?Opto-Acoustic Thrombolysis?, issued 2/8/00; U. S. Patent 6,538,739, ?Bubble Diagnostics?, issued 3/25/03; and U. S. Patent 6,368,318, ?Opto-Acoustic Recanalization Delivery System?, issued 4/9/02. Foreign rights are available in selected countries. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's opto-acoustic recanalization system should provide a written statement of interest, which includes the following: 1. Company Name and address. 2. The name, address, and telephone number of a point of contact. 3. A description of corporate expertise and facilities relevant to commercializing this technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships and Commercialization P.O. Box 808, L-795 Livermore, CA 94551-0808 Attention: FBO61-04 Please provide your written statement within thirty (30) days from the date this announcement is published to ensure consideration of your interest in developing and commercializing LLNL's opto-acoustic recanalization technology.
- Record
- SN00471922-W 20031120/031118211907 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |